Lonsurf

Drug - Lonsurf® (trifluridine and tipiracil) [Taiho Pharmaceutical CO., Ltd.]

May 2016

Therapeutic area - Oncology

Approval criteria (gender specific)

• Patient must be 18 years of age or older AND
• Have a diagnosis of metastatic colorectal cancer AND
• Must have tried and failed or was intolerant to fluoropyrimidine-, oxaliplatin-and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy (such as panitumumab or cetuximab).

Quantity limit

• 15 mg/6.14 mg tablets: Maximum of 100 tablets per 28-day cycle (10 tablets per day per 28-day cycle, based on trifluridine component
• 20 mg/8.19 mg tablets: Maximum of 80 tablets per 28-day cycle (8 tablets per day per 28-day cycle, based on trifluridine component

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411